OMER : Analysis & Opinions
October 17, 2016Omeros Corporation said its OMS721 drug produced positive results for treating kidney diseases in a Phase II trial.
January 2, 2016In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals ...
August 20, 2015Omeros Corporation (OMER), a Seattle-based biopharmaceutical company, reported an additional positive data from a Phase 2 ...
March 25, 2015ETF funds are now very liquid investments and are suitable to investors who seek to match the price performance of the indexes ...